On June 14, 2022, ICER released its draft evidence report, “AMX0035 and Oral Edaravone for Amyotrophic Lateral Sclerosis.” This document provides a framework for considering which aspects of two potential treatments for Amyotrophic Lateral Sclerosis (ALS) are important to patients and their families, and how to consider presenting those perspectives. This guide specifically provides insights about how to read and respond to ICER’s draft evidence report, as well as how to request a slot to make comments during ICER’s public meeting.
Categories
- Access
- Advocacy
- California
- Coalitions
- Comment Letters
- Copay Accumulators
- Copay Assistance
- COVID-19
- Drug Costs
- FDA
- Featured
- Featured Action
- Federal Issues
- Health Insurance
- Health Policy
- ICER
- Illinois
- Issues
- Letters Submitted
- Letters Supported
- Massachusetts
- Medicaid
- Medicare
- Medicare Part D
- News
- Op-Ed
- Out of Pocket Costs
- Pharmacy Benefit Managers
- Podcast
- Prescription Drugs
- Press Releases
- Public Statement
- QALY
- State Issues
- Statements
- Step Therapy
- Surprise Billing
- Uncategorized
- Value Based Insurance Design
- Value Frameworks
- Virtual Advocacy Chat
Tags
21st Century Cures Act
340B
Access to Care
Advocacy
Alzheimer's
Biden Administration
biosimilars
Cancer
cms
Copay Accumulators
copay assistance
COVID-19 Vaccine
drug costs
Drug Manufacturing
Drug Pricing
drug rebate
fail first
FDA
Gene Therapies
H.R.3
Health Insurance
hospital bills
HR 3708
hsa
ICER
Insurance design
Joe Biden
medicare Part B
medicare part D
Mental Health
Nonmedical Switching
open enrollment
Out of Pocket Costs
PBM
PBMs
pharmacy benefit managers
Price Transparency
Prior Authorization
QALY
Rare Disease
Right to Repair
Step Therapy
Telehealth
transparency
Value Framework